Vobramitamab duocarmazine

Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276) . Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity[1].

Product Specifications

CAS Number

[2490556-51-7]

Product Name Alternative

AEX4089DC1; MGC018

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

[Vobramitamabduocarmazine]

References & Citations

[1]Juniper A Scribner, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19 (11) :2235-2244.